Magnus Medical Company Profile

Background

Magnus Medical, Inc., established in 2020 and headquartered in Burlingame, California, is a privately held medical device company dedicated to transforming the treatment of neuropsychiatric disorders. The company's mission is to restore and sustain mental health by developing innovative, non-invasive neuromodulation technologies. Its flagship product, the SAINT™ Neuromodulation System, is designed to provide rapid and individualized treatment for major depressive disorder (MDD), particularly in patients who have not responded to traditional therapies.

Key Strategic Focus

Magnus Medical's strategic focus centers on:

• Personalized Neuromodulation Therapy: Utilizing advanced imaging technologies combined with proprietary algorithms to deliver individualized, non-invasive brain stimulation tailored to each patient's unique neural architecture.

• Accelerated Treatment Protocols: Implementing treatment regimens that achieve significant symptom relief within days, addressing the urgent needs of patients with severe, treatment-resistant depression.

• Regulatory Advancement: Securing FDA approvals and designations to expedite the availability of their innovative therapies to the market.

Financials and Funding

Magnus Medical has successfully secured funding to support its development and commercialization efforts:

• Series A Financing: In October 2021, the company raised $25 million in a Series A financing round co-led by JAZZ Venture Partners and Red Tree Venture Capital.

• Subsequent Funding: In March 2025, Magnus Medical raised approximately $64 million in a Series Unknown funding round.

These funds are allocated towards further development of the SAINT™ Neuromodulation System, conducting clinical trials, and preparing for commercial launch.

Pipeline Development

The primary focus of Magnus Medical's pipeline is the SAINT™ Neuromodulation System:

• Clinical Trials: A double-blinded randomized controlled trial demonstrated that 79% of participants receiving active treatment entered remission, compared to 13% in the sham treatment group.

• Regulatory Milestones: The system received FDA Breakthrough Device Designation in October 2021 and 510(k) clearance in September 2022.

• Commercial Launch: The company announced the commercial launch of the SAINT™ Neuromodulation System in late 2023, with initial customer sites including the University of Arkansas for Medical Sciences, MUSC Health, and California-based Acacia Clinics and Kaizen Brain Center.

Technological Platform and Innovation

Magnus Medical's innovation is encapsulated in the SAINT™ Neuromodulation System, which integrates:

• Advanced Imaging Technologies: Employing structural and functional MRI to identify optimal stimulation targets within the brain.

• Proprietary Algorithms: Utilizing algorithms to personalize treatment by determining precise neural targets and stimulation patterns.

• Non-Invasive Stimulation: Delivering targeted magnetic pulses to modulate neural activity associated with depression, aiming to restore healthy brain function.

Leadership Team

• Christian Gormsen: Chief Executive Officer and President.

• Brandon Bentzley, M.D., Ph.D.: Co-Founder and Chief Science Officer, leading research and development efforts.

• Romain Moreau-Gobard: Chief Technology Officer and Head of Software Engineering, overseeing technological development.

• Joost Schutter: Vice President of Finance and Head of Corporate Function, managing financial operations.

Leadership Changes

In February 2025, the company announced the departure of its President, with the individual transitioning to a new role outside the organization.

Competitor Profile

Market Insights and Dynamics

The global market for neuromodulation devices is experiencing significant growth, driven by increasing prevalence of neuropsychiatric disorders and demand for non-invasive treatment options. The market is characterized by rapid technological advancements and a competitive landscape with several key players.

Competitor Analysis

• Medtronic: A leading medical device company offering a range of neuromodulation therapies for various neurological conditions.

• Boston Scientific: Provides neuromodulation solutions, including deep brain stimulation systems for movement disorders and chronic pain management.

• Abbott: Offers a portfolio of neuromodulation devices targeting chronic pain and movement disorders.

These competitors focus on developing and commercializing neuromodulation technologies, with varying degrees of emphasis on personalized and accelerated treatment protocols.

Strategic Collaborations and Partnerships

Magnus Medical has established significant partnerships to bolster its market position:

• Stanford University: Licensed the SAINT™ technology from Stanford, forming the foundation of the company's neuromodulation system.

• JAZZ Venture Partners and Red Tree Venture Capital: Co-led the Series A financing round, providing financial support and strategic guidance.

Operational Insights

Magnus Medical differentiates itself through:

• Personalized Treatment Approach: Tailoring therapy to individual brain connectivity patterns, enhancing efficacy.

• Rapid Treatment Delivery: Achieving significant symptom relief within days, addressing the needs of patients with severe depression.

• Regulatory Milestones: Securing FDA designations and clearances to expedite market entry and build credibility.

Strategic Opportunities and Future Directions

Looking ahead, Magnus Medical aims to:

• Expand Indications: Explore the application of its neuromodulation technology to other neuropsychiatric disorders.

• Global Market Penetration: Extend its reach beyond the U.S. to address the global burden of treatment-resistant depression.

• Technological Advancements: Continue refining its algorithms and stimulation protocols to enhance treatment outcomes.

Contact Information

• Website: www.magnusmed.com

• LinkedIn: Magnus Medical LinkedIn Profile

• Headquarters: Burlingame, California, United States